Illustrationsfoto Urologie

Publikationen

Publikationen aus der Urologie

 

 

Publikationen 2016

Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K. (2016) 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med 41(7):515-21.

Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester HJ, Vergho D, Becker A. (2016) Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res 6(1):78.

Dell'Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). (2016) Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol Oncol 34(5):234.e13-9.

Kalogirou C, Schäfer D, Krebs M, Kurz F, Schneider A, Riedmiller H, Kneitz B, Vergho D. (2016) Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression. Urol Int 96(1):106-15.

Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A, International Renal Cell Carcinoma-Venous Thrombus Consortium , Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. (2016) Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. J Surg Oncol 114(6):764-768.

Publikationen 2015

Ardelt PU, Ebbing J, Adams F, Reiss C, Arap W, Pasqualini R, Bachmann A, Wetterauer U, Riedmiller H, Kneitz B. (2015) An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder. PLoS ONE 10(3):e0118646.

Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz PI, Van Poppel H, Montorsi F, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). (2015) Natural history of surgically treated high-risk prostate cancer. Urol Oncol 33(4):163.e7-13.

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67(1):74-82.

Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56(6):855-61.

Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT) (2015) Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67(1):157-64.

Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). (2015) Eur Urol 67(2):319-25.

Kocot A, Riedmiller H. (2015) Treatment of long-term radiation injuries in the urinary tract. Urologe A 54(12):1765-71.

Litovkin K, Van Eynde A, Joniau S, Lerut E, Laenen A, Gevaert T, Gevaert O, Spahn M, Kneitz B, Gramme P, Helleputte T, Isebaert S, Haustermans K, Bollen M. (2015) DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS ONE 10(6):e0130651.

Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, Briganti A, Montorsi F, Van Poppel H, Joniau S, Spahn M. (2015) Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. Prostate Cancer Prostatic Dis 18(1):31-7.

Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. (2015) Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol 194(2):304-8.

Riedmiller H, Kocot A. (2015) The devastated bladder outlet: treatment options. Curr Opin Urol 25(4):352-6.

Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. (2015) Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol 193(2):436-42.

Vergho D, Burger M, Schrammel M, Brookman-May S, Gierth M, Hoschke B, Lopau K, Gilfrich C, Riedmiller H, Wolff I, May M. (2015) Matched-pair analysis of renal function in the immediate postoperative period: a comparison of living kidney donors versus patients nephrectomized for renal cell cancer. World J Urol 33(5):725-31.

Publikationen 2014

Gierth M, Fritsche HM, Buchner H, May M, Aziz A, Otto W, Bolenz C, Trojan L, Hermann E, Tiemann A, Müller SC, Ellinger J, Brookman-May S, Stief CG, Tilki D, Nuhn P, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Wieland WF, Riedmiller H, Denzinger S, Bastian PJ, Burger M. (2014) Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. World J Urol 32(2):365-71.

Hailer A, Grunewald TG, Orth M, Reiss C, Kneitz B, Spahn M, Butt E. (2014) Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration. Oncotarget 5(12):4144-4153.

Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Ströbel P, Gessler M, Riedmiller H, Spahn M. (2014) Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 74(9):2591-603.

Kocot A, Riedmiller H. (2014) Management and prevention of complications in open urethral surgery. End-to-end anastomosis and buccal mucosa urethroplasty. Urologe A 53(7):1006-10.

Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M, Kneitz B, Isebaert S, Haustermans K, Beullens M, Van Eynde A, Bollen M. (2014) Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol 140(11):1849-61.

Loeser A, Katzenberger T, Vergho DC, Kocot A, Burger M, Riedmiller H. (2014) Frozen section analysis of ureteral margins in patients undergoing radical cystectomy for bladder cancer: differential impact of carcinoma in situ in the bladder on reliability and impact on tumour recurrence in the upper urinary tract. Urol Int 92(1):50-4.

Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. (2014) Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep 15(5):404.

Schmid M, Steinlein C, Tian Q, Hanlon Newell AE, Gessler M, Olson SB, Rosenwald A, Kneitz B, Fedorov LM. (2014) Mosaic variegated aneuploidy in mouse BubR1 deficient embryos and pregnancy loss in human. Chromosome Res 22(3):375-92.

Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. (2014) Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol 66(3):577-83.

Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, Riedmiller H, Kneitz B. (2014) Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer 14:25.

Vergho DC, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, Spahn M, Löser A, Kocot A, Riedmiller H, Kneitz B. (2014) Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. PLoS ONE 9(10):e109877.

Publikationen 2013

Ardelt P, Grünemay N, Strehl A, Jilg C, Miernik A, Kneitz B, Butt E. (2013) LASP-1, a novel urinary marker for detection of bladder cancer. Urol Oncol 31(8):1591-8.

Aziz A, Gierth M, Fritsche HM, May M, Otto W, Denzinger S, Wieland WF, Merseburger A, Riedmiller H, Kocot A, Burger M. (2013) Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy. Urol Int 91(1):97-102.

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M, European Association of Urology. (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639-53.

Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). (2013) Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 63(4):693-701.

Buchner A, May M, Burger M, Bolenz C, Herrmann E, Fritsche HM, Ellinger J, Höfner T, Nuhn P, Gratzke C, Brookman-May S, Melchior S, Peter J, Moritz R, Tilki D, Gilfrich C, Roigas J, Zacharias M, Hohenfellner M, Haferkamp A, Trojan L, Wieland WF, Müller SC, Stief CG, Bastian PJ. (2013) Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. Eur J Surg Oncol 39(4):372-9.

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234-41.

Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dr?goescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D. (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64(5):846-54.

Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, Soloway M, Solsona E, Sved P, Babjuk M, Brausi MA, Cheng C, Comperat E, Dinney C, Otto W, Shah J, Thürof J, Witjes JA, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):36-44.

Elias J, Heuschmann PU, Schmitt C, Eckhardt F, Boehm H, Maier S, Kolb-Mäurer A, Riedmiller H, Müllges W, Weisser C, Wunder C, Frosch M, Vogel U. (2013) Prevalence dependent calibration of a predictive model for nasal carriage of methicillin-resistant Staphylococcus aureus. BMC Infect Dis 13:111.

Fritsche HM, May M, Denzinger S, Otto W, Siegert S, Giedl C, Giedl J, Eder F, Agaimy A, Novotny V, Wirth M, Stief C, Brookman-May S, Hofstädter F, Gierth M, Aziz A, Kocot A, Riedmiller H, Bastian PJ, Toma M, Wieland WF, Hartmann A, Burger M. (2013) Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol 63(4):739-44.

Gunia S, Burger M, Hakenberg OW, May D, Koch S, Jain A, Birnkammer K, Wieland WF, Otto W, Hofstädter F, Fritsche HM, Denzinger S, Gilfrich C, Brookman-May S, May M. (2013) Inherent grading characteristics of individual pathologists contribute to clinically and prognostically relevant interobserver discordance concerning Broders' grading of penile squamous cell carcinomas. Urol Int 90(2):207-13.

Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H, Kneitz B. (2013) MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci 14(11):21414-34.

Kocot A, Giessing M. (2013) Increasing the donor and recipient pool-expanded criteria in living kidney donors. Transplant Proc 45(3):1245-7.

Kunath F, Keck B, Bertz S, Brookman-May S, May M, Vergho D, Hartmann A, Riedmiller H, Wullich B, Burger M. (2013) Is gender becoming relevant in uro-oncological research? A bibliographical analysis. World J Urol 31(5):1065-72.

Kunath F, Krause SF, Wullich B, Goebell PJ, Engehausen DG, Burger M, Meerpohl JJ, Keck B. (2013) Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov. BMC Urol 13:56.

Loeser A, Neumann M, Kocot A, Vergho DC, Spahn M, Riedmiller H. (2013) Serum carcino-embryonic antigen (CEA) and its possible use as tumor marker for secondary tumors in urinary intestinal reservoirs. Urol Oncol 31(5):644-8.

Loss M, Bald C, Breidenbach T, Engehausen D, Guba M, Klein I, Matevossian E, Müller V, Vergho D, Kleespies A. (2013) Abdominal organ retrieval: strategies to improve quality. Chirurg 84(4):263-70.

May M, Burger M, Otto W, Hakenberg OW, Wieland WF, May D, Hofstädter F, Götz S, Niessl N, Fritsche HM, Birnkammer K, Gilfrich C, Peter J, Jain A, Koch S, Lebentrau S, Riedmiller H, Rössler W, Denzinger S, Brookman-May S, Gunia S. (2013) Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis. BJU Int 112(4):E383-90.

May M, Ficarra V, Shariat SF, Zigeuner R, Chromecki T, Cindolo L, Burger M, Gunia S, Feciche B, Wenzl V, Aziz A, Chun F, Becker A, Pahernik S, Simeone C, Longo N, Zucchi A, Antonelli A, Mirone V, Stief C, Novara G, Brookman-May S, CORONA and SATURN projects , Young Academic Urologists Renal Cancer Group. (2013) Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. J Urol 190(2):458-63.

Otto W, Denzinger S, Fritsche HM, Burger M, Rößler W, Bertz S, May M, Hartmann A, Hofstädter F, Wieland WF, Eder F. (2013) Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundr. Clin Genitourin Cancer 11(4):537-44.

Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF, European Association of Urology. (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059-71.

Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B. (2013) Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS ONE 8(6):e65064.

Stoehr R, Taubert H, Gaisa NT, Smeets D, Kneitz B, Giedl J, Ruemmele P, Wieland WF, Rau TT, Hartmann A. (2013) Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 230(4):453-6.

Publikationen 2012

Ardelt PU, Woodhouse CR, Riedmiller H, Gerharz EW. (2012) The efferent segment in continent cutaneous urinary diversion: a comprehensive review of the literature. BJU Int 109(2):288-97.

Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. (2012) Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 61(3):584-92.

Fritsche HM, Aziz A, Eder F, Otto W, Denzinger S, Wieland WF, May M, Hofstädter F, Hartmann A, Burger M. (2012) Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens. Virchows Arch 461(6):655-61.

Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M. (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188(1):58-62.

Joniau S, Hsu CY, Gontero P, Spahn M, Van Poppel H. (2012) Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol 46(3):164-71.

Kälble T, Hofmann I, Thüroff JW, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truß M, Roth S, von Rundstedt FC, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M, Bader P, Steffens J, Harzmann R, Stief CG, Karl A, Müller SC, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübben H, Juenemann KP, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon WF, Miller S, Weingärtner K, Schilling A, Piechota H, Becht JE, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M. (2012) Secondary malignancies in urinary diversions. Urologe A 51(4):500, 502-6.

Kocot A, Vergho DC, Riedmiller H. (2012) Use of bowel segments for ureter reconstruction. Urologe A 51(7):928-36.

Otto W, May M, Fritsche HM, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, Tilki D, Buchner A, Höfner T, Brookman-May S, Nuhn P, Gilfrich C, Roigas J, Zacharias M, Denzinger S, Hohenfellner M, Haferkamp A, Müller SC, Kocot A, Riedmiller H, Wieland WF, Stief CG, Bastian PJ, Burger M. (2012) Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med 9(6):481-9.

Otto W, Nowrotek A, Burger M, Wieland WF, Rößler W, Denzinger S. (2012) Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic]. Aktuelle Urol 43(3):162-6.

Otto W, Rubenwolf PC, Burger M, Fritsche HM, Rößler W, May M, Hartmann A, Hofstädter F, Wieland WF, Denzinger S. (2012) Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer. BMC Cancer 12:459.

Papoutsoglou N, Tappe D, Demmer P, Kocot A, Riedmiller H. (2012) Urinary incontinence due to the presence of necrotic adult Schistosoma haematobium parasite in the bladder following travel to Egypt. Travel Med Infect Dis 10(4):205-7.

Riedmiller H. (2012) Comments on nephrectomy - laparoscopic versus robotic. Urologe A 51(5):669-70.

Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research Group. (2012) Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. J Urol 188(1):84-90.

Tekgül S, Riedmiller H, Hoebeke P, Ko?vara R, Nijman RJ, Radmayr C, Stein R, Dogan HS, European Association of Urology. (2012) EAU guidelines on vesicoureteral reflux in children. Eur Urol 62(3):534-42.

Vergho D, Kocot A, Bauer C, Riedmiller H. (2012) Insufficiency of the efferent segment in continent cutaneous diversion. Urologe A 51(4):485-93.

Kontakt, Öffnungszeiten, Sprechzeiten

Öffnungszeiten:

Allgemeine Sprechstunde
Montag bis Freitag 8:00 Uhr bis 14:30 Uhr

Sprechstunde Privatambulanz
nur nach Absprache

Terminvergabe stationärer Aufenthalt
Montag bis Freitag 8:30 Uhr bis 14:00 Uhr
Telefon: +49 931 201-32090

 

 

Telefon:

Sekretariat Prof. Kübler
Marita Riedl
Telefon: +49 931 201-32001

Anmeldung Ambulanz
Hanna Ziegler
Telefon: +49 931 201-32100 oder
Telefon: +49 931 201-32101

Anmeldung zur stationären Aufnahme
Kathrin Nätscher und
Katharina Kasumow
Telefon: +49 931 201-38090

Anmeldung zu Privatsprechstunden
Özlem Brenca
Sr. Angelika
Telefon: +49 931 201-32002

E-Mail:

Klinikdirektion
E-Mail: urologie@ ukw.de

Fax:

Klinikdirektion
Fax: +49 931 201-32009

Spezialsprechstunden
Fax: +49 931 201-32109

Privatsprechstunde
Fax: +49 931 201-32003


Anschrift:

Klinik und Poliklinik für Urologie und Kinderurologie des Universitätsklinikums | Zentrum Operative Medizin (ZOM) | Oberdürrbacher Straße 6 | Haus A2 | 97080 Würzburg | Deutschland